Skip to content
OpenCapital
Get started

Kodiak Sciences Inc KOD Interest coverage

Interest coverage at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
75.6×-4.5×
HRO
HarrowHROW
0.9×+0.7×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-49.3×-20.0×
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-25.8×+35.4×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-13×-15.9×
Vera Therapeutics logo
Vera TherapeuticsVERA
-50.7×+1,690×

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

ebit/interest expense=-42,382.4×

Based on trailing twelve months.

The official record: Kodiak Sciences Inc’s 10-Q, filed August 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's interest coverage?
Kodiak Sciences Inc (KOD) reported interest coverage of -42,382.4× in Q2 2024.
How has Kodiak Sciences Inc's interest coverage changed year-over-year?
Kodiak Sciences Inc's interest coverage decreased by 116.7% year-over-year, from -19,561.9× to -42,382.4×.
What is the long-term trend for Kodiak Sciences Inc's interest coverage?
Over 3 years (2020 to 2023), Kodiak Sciences Inc's interest coverage has grown at a 57.7% compound annual growth rate (CAGR), from -5,440.3× to -21,332.4×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.